Revolutionizing Cancer Detection with DNA Methylation
Pioneering molecular diagnostics through exclusive TAGMe™ liquid biopsy technology for early cancer screening, precise diagnosis, and recurrence monitoring.
This page is not the official website. Generated by AI, does not constitute any advice. If needed, please click here to visit the corresponding official website.
Pioneering molecular diagnostics through exclusive TAGMe™ liquid biopsy technology for early cancer screening, precise diagnosis, and recurrence monitoring.
Founded in 2018 by top epigenetic experts, Epiprobe is a high-tech enterprise dedicated to the molecular diagnosis of cancer DNA methylation and precision theranostics. Our mission is to keep everyone away from cancer by leveraging cutting-edge innovations in epigenetics and artificial intelligence.
Based on years of research and clinical validation, we have developed an exclusive patent-protected liquid biopsy technology — TAGMe™ — that combines big data analytics and AI to detect cancer at its earliest stages through DNA methylation patterns in blood, urine, and tissue samples.
Keep everyone away from cancer through early detection and precision diagnostics.
Build a cancer-free world by transforming molecular diagnostics.
Convince with products — innovation, quality, and reliability above all.
Tumor Aligned General Methylated Epiprobe — Worldwide Exclusive Liquid Biopsy Technology
TAGMe™ represents a breakthrough in precision oncology, offering clinicians a powerful tool for comprehensive cancer management.
Detect cancer before symptoms appear using non-invasive liquid biopsies.
Support clinical decisions with accurate molecular profiling of suspicious lesions.
Monitor response to surgery or chemotherapy through dynamic methylation changes.
Enable long-term surveillance with periodic liquid biopsies to catch relapse early.
Innovative DNA Methylation Detection Kits & Sample Preparation Tools
In vitro qualitative detection of hypermethylation of the gene PCDHGB7 in cervical specimens.
In vitro qualitative detection of hypermethylation of the gene PCDHGB7 in cervical specimens.
In vitro qualitative detection of hypermethylation of the UC gene in urothelial specimens.
Plasma ctDNA methylation test for early screening and accurate monitoring of multiple cancers.
Dual-purpose kit for detecting PCDHGB7 hypermethylation in female reproductive tract specimens.
Designed for safe collection, transportation, and storage of urine samples for molecular testing.
Magnetic bead-based system for extraction, enrichment, and purification of nucleic acids.
Advanced version with optimized buffer system for higher yield and purity of nucleic acids.
Epiprobe announced the independent development of three cancer gene methylation detection kits, marking a significant milestone in non-invasive diagnostics.
Gong Yi’an® PCDHGB7 gene methylation detection kit receives regulatory recognition, setting a new standard in molecular diagnostics.
Shanghai Epiprobe Biotechnology receives approval for the world’s first Class III methylation-based cancer detection kit.
For inquiries about our products, partnerships, or technical support, please visit our official website.
Email: info@epiprobe.com
Phone: +8619946281332
Company: Shanghai Epiprobe Biotechnology Co., Ltd.
Notice for Buyers: If you are a buyer, the above information is generated by AI collection and does not constitute any advice. If necessary, please visit the corresponding official website.
For Domain Owners: If you are the domain owner and do not want to be included by fobcompany.info, please contact support@fobcompany.info via your corporate email to cancel. We will cancel your inclusion within 3 business days.
如果您是域名所有者 不想被fobcompany.info收录 请用企业邮箱联系support@fobcompany.info 取消收录 我们将在3个工作日取消您的收录
Service Request: If you are other domain and want to be included, please contact support@fobcompany.info
如果您是其他域名合作 也请联系support@fobcompany.info